Perrigo Remains Committed To Splitting Off Prescription Despite Delay
Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.
You may also be interested in...
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
The head of the UK’s health technology assessment body NICE is stepping down, while the country’s medicines agency, the MHRA, will have an interim chief in the run-up to the UK’s planned Brexit from the European Union on 31 October.